2 London-listed stocks I’d buy

I think Glanbia (LON:GLB) and Tate & Lyle (LON:TATE) are two stocks to buy to ride the rising consumer interest in health and nutrition.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One stock that’s caught my eye is global nutrition group Glanbia (LSE:GLB). It’s enjoying a surge in growth as consumer trends in health, wellness and nutrition gain prominence. The group sells the Optimum Nutrition and SlimFast brands, as well as a popular vitamin and mineral premix. It also has a dairy division, sports nutrition, and speciality non-dairy ingredients. It’s a €4bn company based in Ireland.

Glanbia share price activity

The Glanbia share price has risen 34% year-to-date and is now trading at €14 a share. But it’s down 25% from early 2019. It fell back then after global trade wars impacted earnings. And the share price drop was exacerbated further by Covid-19.

The company has been growing through acquisitions, which continue to improve its future potential. And it’s particularly seeing strong growth across e-commerce. This gives it confidence that its adjusted earnings per share growth will be at the upper end of the growth range it predicted.

But it’s not all rosy. Glanbia has seen a drop in revenues from cheese and it’s also facing a legal dispute over the construction of a new cheese factory in Ireland to which it will supply milk. The National Trust for Ireland (An Taisce) is against the new build for environmental reasons. As the country is trying to reduce emissions to meet the Paris Agreement, they argue a new factory won’t help.

Last month the High Court supported the Glanbia factory build, but An Taisce is appealing this decision.

Would I buy shares in Glanbia?

Glanbia’s price-to-earnings ratio (P/E) is 17, earnings per share (EPS) are 79c while the dividend yield is 1.7%. Between 2015 and 2019, the Glanbia share price consistently sat above where it is today. I think this shows strength and resilience.

I’m tempted to buy shares in Glanbia because it’s providing many of the consumer goods people want today. Nutrition has never been more on the minds of consumers and I think this trend will continue.

Further focus on health and nutrition

The other stock I like is Tate & Lyle (LSE:TATE). It supplies food and beverage ingredients to industrial markets.

As I noted above, there’s a clear trend that consumers want to be healthier, and Tate & Lyle’s got the expertise to make processed foods healthier. Last month Tate announced it’s looking into selling a controlling stake in its commercial sweeteners unit. This would allow it to focus more closely on healthier products through its food and beverage solutions unit. This division makes texturants, stabilisers and low-calorie sweeteners.

I think this seems like a sensible focus for the group and it could benefit shareholders long term. In the past three years, the Tate & Lyle share price has risen 33%. Historically it’s been a volatile investment, but the dividend helps long-term shareholders withstand the low points. It was relegated from the FTSE 100 to the FTSE 250 in 2014 for the 12th time in 23 years. It’s not yet made it back in, but streamlining the business seems like a good way to improve its prospects.

Tate & Lyle has a price-to-earnings ratio (P/E) of 13 and earnings per share (EPS) are 52p. Its dividend yield is around 3.6%.

Glanbia and Tate & Lyle are two stocks I’d buy to follow the health and wellness trend and the e-commerce rise. I own Tate & Lyle shares and would be happy to add more to my Stocks and Shares ISA.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen owns shares of Tate & Lyle. The Motley Fool UK has recommended Glanbia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father holding daughter in a field of cows
Investing Articles

A FTSE 100 share that could create generational wealth

Investing in FTSE shares can help individuals pass down a significant chunk of cash to their children and grandchildren, data…

Read more »

Investing Articles

Here’s what the BT share price could mean for passive income investors

The BT share price has been falling for years, but that might be about to change. And dividends could be…

Read more »

Investing Articles

At £4.76, is the Aviva share price a steal? Here’s what the charts say!

Aviva has outperformed the Footsie over the last year. But is there still value in its share price? This Fool…

Read more »

Photo of a man going through financial problems
Investing Articles

Does a 43% price drop make this undervalued UK stalwart one of the best cheap shares to buy now?

After losing a third of its value of the past five years, this might be one of the most undervalued…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

My top 3 picks today for a £20,000 Stocks and Shares ISA

Here are three very different investments to consider for a Stocks and Shares ISA, covering both the UK and US…

Read more »

Businesswoman calculating finances in an office
Investing Articles

The Darktrace share price has been surging — and it could climb higher

I think the Darktrace share price could have more room to run. Despite the competitive AI industry, the firm looks…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

With its 7% dividend, should I be watching the Aviva share price?

Dividend investors will struggle to find many companies with a yield above 7%, so should the Aviva share price be…

Read more »

Investing Articles

Could this be one of the FTSE 100’s best cheap dividend shares?

Looking for the best dividend growth shares to buy? Our writer Royston Wild thinks this FTSE 100 housebuilder might well…

Read more »